Sta compact coagulation analyser

The anticoagulant activity was determined with prothrombin time (PT) and activated partial thromboplastin time (APTT) following the standard method described by [21 ]. 250 μL of human platelet-poor-plasma was incubated in a reaction vial with 100 μL of different concentrations of BVME, BVPE, BVAE, TPME, TPPE, TPME, OSME, OSPE, and OSAE (50, 25, and 12.5 mg/mL, respectively) for 7 minutes at room temperature before being subjected to PT and APTT tests.
Neoplastin Cl Plus reagent and STA-PTT automated reagent, Diagnostica Stago (Asnieres-sur-Seine, France), were reconstituted and subjected to PT and APTT assays, together with 0.025M calcium chloride. The PT and APTT assays were analysed using STA Compact coagulation analyser (Diagnostica Stago, France) according to the manufacturer's protocol. The time taken for clot formation was detected using the analyser and compared with the PT and APTT from control (without extracts) as the negative control and plasma mixed with heparin sodium salt (140 IU/mg) (Sigma-Aldrich, USA) as the positive control. All experiments were carried out in triplicate.

In vitro intrinsic anticoagulant pathway was measured by activated partial thromboplastin time (APTT). Standard human normal pooled plasma was spiked with equal volume of different concentrations of M. malabathricum crude extract and fractions (1 mg/mL, 500 μg/mL, 250 μg/Ml, and 125 μg/mL). Meanwhile, STA-PTT automated reagent was reconstituted and subjected to APTT assay, together with 0.025 M calcium chloride. The APTT assay was analysed using STA Compact coagulation analyser (Diagnostica Stago, Asnieres-sur-Seine, France) according to the manufacturer's protocol. The anticoagulant activity was measured by using a parallel standard curve based on the standard calibration curve for heparin sodium salt (140 IU/mg).